 Harrow Health Inc NASDAQ:HROW revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food and Drug Administration FDA approved ophthalmic products from the Novartis group of companies. The Nashville, Tennessee-based eye care pharmaceutical company said the acquisition, when closed, will further expand Harrows portfolio of branded pharma products and its ability to serve the US ophthalmic surgical and acute care markets. 